CN-121971415-A - Application of apocynin in preparing medicine for preventing and/or treating psoriasis

Abstract

The invention provides application of apocynin in preparation of a medicament for preventing and/or treating psoriasis, and belongs to the technical field of skin medicament preparation. Application of apocynin in preparing medicine for preventing and/or treating psoriasis or psoriasis complication is provided. The invention takes a psoriasis mouse model as an object, verifies the drug effect of the apocynin, can effectively relieve the phenotype of the psoriasis mouse model, inhibit the skin damage progress and has remarkable treatment effect on the psoriasis. The invention provides a new medical application for apocynin, and a new therapeutic drug for treating psoriasis, has wide application prospect and great clinical popularization value.

Inventors

• TAI ZONGGUANG
• CHEN ZHONGJIAN
• ZHU QUANGANG
• ZHOU HANXUE
• CHU XINTONG
• CHEN QILONG
• YIN BEI
• LIU JUN
• ZHANG CAIYUN

Assignees

• 上海市皮肤病医院

Dates

Publication Date

20260505

Application Date

20251215

Claims (10)

1. 1. Application of apocynin in preparing medicine for preventing and/or treating psoriasis or psoriasis complication is provided.
2. 2. The use according to claim 1, wherein the psoriasis complications comprise at least one of psoriatic arthritis, cardiovascular disease and inflammatory bowel disease.
3. 3. The psoriasis treating medicine is characterized by comprising apocynin and pharmaceutically acceptable auxiliary materials.
4. 4. A psoriasis treating medicament according to claim 3, wherein the formulation of the medicament comprises a topical paste.
5. 5. The psoriasis treatment drug according to claim 4, wherein the topical paste comprises the following components in parts by weight: 1-2 parts of apocynin, 4-6 parts of polyethylene glycol-7-stearate, 2-4 parts of cetyl alcohol, 3-5 parts of medium chain triglyceride, 0.5-1.5 parts of glyceryl monostearate, 0.005 part of ethylparaben, 6.5-8.5 parts of surfactant and 30-31 parts of ultrapure water.
6. 6. The psoriasis treatment drug according to claim 5, wherein the topical paste comprises the following components in parts by weight: 2 parts of apocynin, 5 parts of polyethylene glycol-7-stearate, 3 parts of cetyl alcohol, 4 parts of medium chain triglyceride, 1 part of glyceryl monostearate and ethyl hydroxybenzoate, 0.005 part of surfactant and 30.2 parts of ultrapure water.
7. 7. The psoriasis treatment medication of claim 5 or 6, wherein the surfactant comprises diethylene glycol monoethyl ether.
8. 8. The psoriasis treatment drug according to claim 5 or 6, wherein the preparation method of the external ointment comprises the steps of: Mixing polyethylene glycol-7-stearate, cetyl alcohol, medium chain triglyceride, glyceryl monostearate and ethylparaben to obtain a first component; mixing and dissolving apocynin and a surfactant to obtain a second component; Fully mixing the first component with ultrapure water to obtain a third component; mixing and homogenizing the third component and the second component.
9. 9. The psoriasis treatment medication of claim 8, wherein the temperature of thorough mixing is 80-90 ℃.
10. 10. The psoriasis treatment drug according to claim 8, wherein the mixing and homogenizing time is 2-5 min.

Description

Application of apocynin in preparing medicine for preventing and/or treating psoriasis Technical Field The invention belongs to the technical field of skin medicament preparation, and particularly relates to application of apocynin in preparation of a medicament for preventing and/or treating psoriasis. Background Psoriasis is a chronic inflammatory skin disease mediated by immunity, involving complex interactions between infiltrating immune cells and keratinocytes, the pathogenesis of which has not been fully elucidated. The pathological characteristics are mainly represented by the hyperproliferation and differentiation disorder of epidermal keratinocytes, the unbalance of the immune system, inflammatory cells such as neutrophils, mast cells, congenital lymphocytes and T cell infiltration. The patients with psoriasis have large number, long disease course and easy recurrence, and are often accompanied by various complications such as psoriasis arthritis, cardiovascular diseases, inflammatory bowel diseases, metabolic syndrome, anxiety and the like, which generate great burden on mental health and life quality of patients. The existing treatment method for the diseases still faces the problem of poor curative effect, and a new medicine with good curative effect needs to be found, so that the method has important significance. Disclosure of Invention The invention aims to provide application of apocynin in preparing medicines for preventing and/or treating psoriasis. The invention provides application of apocynin in preparing medicines for preventing and/or treating psoriasis or psoriasis complications. Preferably, the psoriasis complications include at least one of psoriatic arthritis, cardiovascular disease and inflammatory bowel disease. The invention provides a psoriasis treatment medicine, which comprises apocynin and pharmaceutically acceptable auxiliary materials. Preferably, the dosage form of the medicament comprises an external ointment. Preferably, the external ointment comprises the following components in parts by weight: 1-2 parts of apocynin, 4-6 parts of polyethylene glycol-7-stearate, 2-4 parts of cetyl alcohol, 3-5 parts of medium chain triglyceride, 0.5-1.5 parts of glyceryl monostearate, 0.005 part of ethylparaben, 6.5-8.5 parts of surfactant and 30-31 parts of ultrapure water. Preferably, the external ointment comprises the following components in parts by weight: 2 parts of apocynin, 5 parts of polyethylene glycol-7-stearate, 3 parts of cetyl alcohol, 4 parts of medium chain triglyceride, 1 part of glyceryl monostearate and ethyl hydroxybenzoate, 0.005 part of surfactant and 30.2 parts of ultrapure water. Preferably, the surfactant comprises diethylene glycol monoethyl ether. Preferably, the preparation method of the external ointment comprises the following steps: Mixing polyethylene glycol-7-stearate, cetyl alcohol, medium chain triglyceride, glyceryl monostearate and ethylparaben to obtain a first component; mixing and dissolving apocynin and a surfactant to obtain a second component; Fully mixing the first component with ultrapure water to obtain a third component; mixing and homogenizing the third component and the second component. Preferably, the temperature of the thorough mixing is 80-90 ℃. Preferably, the mixing and homogenizing time is 2-5 min. The invention provides application of apocynin in preparing medicines for preventing and/or treating psoriasis or psoriasis complications. The invention takes a psoriasis mouse model as an object, and verifies the drug effect of apocynin. The results show that the apocynin can effectively relieve the phenotype of a psoriasis mouse model, inhibit the development of skin lesions and have remarkable treatment effect on psoriasis. The invention provides a new medical application for apocynin, and a new therapeutic drug for treating psoriasis, has wide application prospect and great clinical popularization value. Drawings FIG. 1 is a graph showing the effect of apocynin in treating psoriasis in a model mouse; FIG. 2 is a PASI score for each group of psoriatic mice, wherein Representing a significant difference P <0.05 between the two groups; representing a significant difference P <0.001 between the two groups; FIG. 3 shows spleen index of each group of psoriatic mice, wherein P <0.05, ns, no significant difference between the two groups; FIG. 4 is an appearance of spleens from each group of psoriatic mice; Representative images of HE staining at skin lesions of each group of psoriatic mice in FIG. 5 are shown on a scale of 100. Mu.m. Detailed Description The invention provides application of apocynin in preparing medicines for preventing and/or treating psoriasis or psoriasis complications. In the present invention, the psoriasis is a typical inflammatory disease of the skin, manifested as erythema and scaling. In the examples of the present invention, psoriasis model mice were constructed using Imiquimod (IMQ). The psoriasis model mice s